ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
235.88
-0.22 (-0.09%)
At close: Apr 25, 2025, 4:00 PM
237.00
+1.12 (0.47%)
After-hours: Apr 25, 2025, 6:31 PM EDT
ResMed Employees
ResMed had 9,980 employees as of June 30, 2024. The number of employees decreased by 160 or -1.58% compared to the previous year.
Employees
9,980
Change (1Y)
-160
Growth (1Y)
-1.58%
Revenue / Employee
$503,159
Profits / Employee
$131,589
Market Cap
34.59B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 9,980 | -160 | -1.58% |
Jun 30, 2023 | 10,140 | 1,980 | 24.26% |
Jun 30, 2022 | 8,160 | 190 | 2.38% |
Jun 30, 2021 | 7,970 | 200 | 2.57% |
Jun 30, 2020 | 7,770 | 530 | 7.32% |
Jun 30, 2019 | 7,240 | 1,300 | 21.89% |
Jun 30, 2018 | 5,940 | -140 | -2.30% |
Jun 30, 2017 | 6,080 | 830 | 15.81% |
Jun 30, 2016 | 5,250 | 910 | 20.97% |
Jun 30, 2015 | 4,340 | 240 | 5.85% |
Jun 30, 2014 | 4,100 | 200 | 5.13% |
Jun 30, 2013 | 3,900 | 200 | 5.41% |
Jun 30, 2012 | 3,700 | 250 | 7.25% |
Jun 30, 2011 | 3,450 | 250 | 7.81% |
Jun 30, 2010 | 3,200 | 300 | 10.34% |
Jun 30, 2009 | 2,900 | 200 | 7.41% |
Jun 30, 2008 | 2,700 | 0 | - |
Jun 30, 2007 | 2,700 | 200 | 8.00% |
Jun 30, 2006 | 2,500 | 573 | 29.74% |
Jun 30, 2005 | 1,927 | 407 | 26.78% |
Jun 30, 2004 | 1,520 | 56 | 3.83% |
Jun 30, 2003 | 1,464 | 214 | 17.12% |
Jun 30, 2002 | 1,250 | 297 | 31.16% |
Jun 30, 2001 | 953 | 348 | 57.52% |
Jun 30, 2000 | 605 | 104 | 20.76% |
Jun 30, 1999 | 501 | 111 | 28.46% |
Jun 30, 1998 | 390 | 106 | 37.32% |
Jun 30, 1997 | 284 | 55 | 24.02% |
Jun 30, 1996 | 229 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RMD News
- 3 days ago - ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - Benzinga
- 3 days ago - ResMed: Cornering The Market In Sleep Solutions - Seeking Alpha
- 4 days ago - ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - ResMed slightly beats quarterly profit estimates on sleep devices demand - Reuters
- 4 days ago - Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 - GlobeNewsWire
- 6 days ago - Resmed Names Salli Schwartz as Chief Investor Relations Officer - GlobeNewsWire
- 24 days ago - Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US - GlobeNewsWire
- 25 days ago - Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 - GlobeNewsWire